• 29 Mar 2024
• Admin
• News Article

Biocon Becomes First to Obtain Approval for Liraglutide

Biocon is the First Generics Company to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K.

Overview

Biocon Limited, an innovation-led global biopharmaceuticals company, announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (6mg/ml solution for injection in pre-filled pen), which was filed through its European partner, Zentiva.

About Liraglutide

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus, a disorder in which the body does not produce enough or respond normally to insulin, causing blood sugar (glucose) levels to be abnormally high.

Words from CEO: Biocon Ltd  

Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said: “The approval of Liraglutide, a vertically integrated product, is an important milestone for us. Being the first generic Liraglutide approved in a major regulated/ICH market, it strengthens our leadership in delivering many ‘firsts’ on complex drug products such as bTrastuzumab, bPegfilgrastim, and the first interchangeable biosimilar Insulin Glargine, approved by the U.S. FDA. The approval is also testament to the Company’s strong focus on GLPs and peptides as important future growth drivers for the generics business. Our efforts will now be directed towards commercializing this asset expeditiously in the U.K., in partnership with Zentiva.”

Words from CEO: Zentiva

Steffen Saltofte, CEO Zentiva, commented: “The partnership with Biocon on Liraglutide reaffirms the strong position of Zentiva in the area of diabetes and is a prerequisite for entering into new therapeutic areas, such as obesity. We are proud to have obtained approval for the first Liraglutide generic, that will allow people access to the high-quality and affordable medicines they depend on.”

According to IQVIA MAT Q4 2023 the total addressable market opportunity for GLP-1 in diabetes and weight loss in U.K. was US $425 million.

About Biocon Limited:

• Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. 
• It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. 
• It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com

About Zentiva:

• Zentiva is a Pan-European company developing, manufacturing and delivering high-quality and affordable medicines to more than 100 million people in Europe. 
• Zentiva has 4 wholly owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. 
• We offer solutions in key therapeutical areas like Cardiology & Circulation, Diabetes, Oncology, Respiratory, CNS, and focus on expanding our portfolio in self-care. 
• The company is Private Equity owned, delivering sustainable double-digit growth, with an ambitious 5 -year plan for further strong (organic and inorganic) growth across Europe. 
• We are a team of 5,000 unique talents united to provide health and wellbeing to all generations. 
• We want Zentiva to be a great place to work, where everyone feels welcomed and appreciated, and can be their true selves contributing to the best of their ability.